BioLingus -Cytokine Stabilisation and Slow Release (CSSR) Technology

The Cytokine Stabilisation and Slow Release (CSSR) technology is the "mother" of the BioLingus technologies.

It is the first generation of our technology, which we have further differentiated into:

• SEED : for stabilization of biological materials
• OPUS : for oral and mucosal administration of peptides and small proteins
• SLIT : for mucosal administration and lymphatic delivery of immunotherapies
• The technology consists for 3 pillars : namely formulation, processing and proprietary encapsulation equipment.

Potential Platform Advantages

• Practical & Convenient administration for Chronic Diseases
• Patient preferred : increased treatment uptake
• Elderly population and children (no swallowing)
• Sublingual route : no or less GI side effects
• Flexible dosing - Low production costs
• No or less intensive cold chain
• Extend product lifecycle /new patents
• New indications or more mild indications
• Lymphatic delivery of immuno-active molecules